/주식/MRNA
MRNA

MRNA

USD

Moderna Inc. Common Stock

$23.750-0.890 (-3.612%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$24.640

고가

$25.150

저가

$23.710

거래량

13.75M

기업 기본 정보

시가총액

9.3B

산업

생명공학

국가

United States

거래 통계

평균 거래량

11.01M

거래소

NMS

통화

USD

52주 범위

저가 $23.15현재가 $23.750고가 $56.695

관련 뉴스

CNBC

November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk

Here are five key things investors need to know to start the trading day.

더 보기
November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk
Analyst Upgrades

UBS Maintains Buy on Moderna, Lowers Price Target to $40

UBS analyst Eliana Merle maintains Moderna with a Buy and lowers the price target from $70 to $40.

더 보기
UBS Maintains Buy on Moderna, Lowers Price Target to $40
AccessWire

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers

더 보기
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
Analyst Upgrades

JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25

JP Morgan analyst Jessica Fye maintains Moderna with a Underweight and lowers the price target from $26 to $25.

더 보기
JP Morgan Maintains Underweight on Moderna, Lowers Price Target to $25
Analyst Upgrades

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.

더 보기
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
AccessWire

Moderna to Host Investor Event - Analyst Day

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.The event will include

AccessWire

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patientsCompany does not anticipate any impact to its 2025

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기